Search Results - "Shepherd, L.E."

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials by Yerushalmi, R., Dong, B., Chapman, J.W., Goss, P.E., Pollak, M.N., Burnell, M.J., Levine, M.N., Bramwell, V.H.C., Pritchard, K.I., Whelan, T.J., Ingle, J.N., Shepherd, L.E., Parulekar, W.R., Han, L., Ding, K., Gelmon, K.A.

“…We hypothesized that increased baseline BMI and BMI change would negatively impact clinical outcomes with adjuvant breast cancer systemic therapy. Data from…”
Get full text

Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole by Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Livingston, R.B., Davidson, N.E., Perez, E.A., Chavarri-Guerra, Y., Cameron, D.A., Pritchard, K.I., Whelan, T., Shepherd, L.E., Tu, D.

“…MA17 showed improved outcomes in postmenopausal women given extended letrozole (LET) after completing 5 years of adjuvant tamoxifen. Exploratory subgroup…”
Get full text

Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trial by Davison, K., Chen, B.E., Kukreti, V., Couban, S., Benger, A., Berinstein, N.L., Kaizer, L., Desjardins, P., Mangel, J., Zhu, L., Djurfeldt, M.S., Hay, A.E., Shepherd, L.E., Crump, M.

“…High-dose therapy and autologous stem cell transplantation (ASCT) is often considered for older patients (age >60 years) with relapsed/refractory aggressive…”
Get full text

Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27 by Strasser-Weippl, K., Sudan, G., Ramjeesingh, R., Shepherd, L.E., O'Shaughnessy, J., Parulekar, W.R., Liedke, P.E.R., Chen, B.E., Goss, P.E.

“…Histological subtype, (invasive ductal breast cancer (IDBC)/invasive lobular breast cancer (ILBC)), might be a marker for differential response to endocrine…”
Get full text

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma by Hay, A.E., Klimm, B., Chen, B.E., Goergen, H., Shepherd, L.E., Fuchs, M., Gospodarowicz, M.K., Borchmann, P., Connors, J.M., Markova, J., Crump, M., Lohri, A., Winter, J.N., Dörken, B., Pearcey, R.G., Diehl, V., Horning, S.J., Eich, H.T., Engert, A., Meyer, R.M.

“…Treatment options for patients with nonbulky stage IA–IIA Hodgkin lymphoma include combined modality therapy (CMT) using doxorubicin, bleomycin, vinblastine…”
Get full text

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial by O’Malley, F. P., Chia, S., Tu, D., Shepherd, L. E., Levine, M. N., Huntsman, D., Bramwell, V. H., Andrulis, I. L., Pritchard, K. I.

“…Overexpression of topoisomerase II protein (topo 2α) is postulated to be more closely associated with responsiveness to anthracycline-containing chemotherapy…”
Get full text

15P A Novel RNA Test to Guide Primary Systemic Breast Cancer Chemotherapy by Trudeau, M.E., Pritzker, L.B., Parissenti, A.M., Wang, X., Zhu, M., Guo, B., Shepherd, L.E., Chapman, J.W., Pritzker, K.P.H.

Get full text

Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials by Hilton, J. F., Bouganim, N., Dong, B., Chapman, J. W., Arnaout, A., O’Malley, F., Gelmon, K. A., Yerushalmi, R., Levine, M. N., Bramwell, V. H. C., Whelan, T. J., Pritchard, K. I., Shepherd, L. E., Clemons, M.

“…The AJCC staging criteria consider tumor size to be the largest dimension of largest tumor. Some case series suggest using summation of all tumor dimensions in…”
Get full text

Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 by Ingle, J. N., Tu, D., Pater, J. L., Muss, H. B., Martino, S., Robert, N. J., Piccart, M. J., Castiglione, M., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J., Goss, P. E.

“…Background: MA.17 evaluated letrozole or placebo after 5 years of tamoxifen and showed significant improvement in disease-free survival (DFS) for letrozole…”
Get full text

Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer by Moy, B, Tu, D, Pater, JL, Ingle, JN, Shepherd, LE, Whelan, TJ, Goss, PE

“…Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been…”
Get full text

Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma by Macdonald, D. A., Ding, K., Gospodarowicz, M. K., Wells, W. A., Pearcey, R. G., Connors, J. M., Winter, J. N., Horning, S. J., Djurfeldt, M. S., Shepherd, L. E., Meyer, R. M.

“…Background: In the National Cancer Institute of Canada Clinical Trials Group/Eastern Cooperative Oncology Group HD.6 trial, progression-free survival was…”
Get full text

Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the National Cancer Institute of Canada Clinical Trials Group MY.11 trial by White, D J, Paul, N, Macdonald, D A, Meyer, R M, Shepherd, L E

“…Oral melphalan and prednisone remain an effective and tolerable treatment for patients with multiple myeloma. For approximately 40 years, this combination has…”
Get full text

Acute lymphoblastic leukaemia presenting with hypercalcaemia by Moncrieff, M W, Emerson, P M, Windebank, K P, Shepherd, L E

Get more information